Stock Markets: Nasdaq

Harding and Company – IPO Market – 2nd Half of 2018 Preview

Top IPO's for 2018 Harding and Company looks at what is in store for the remainder of the 2018 IPO Calendar, highlighting the major players looking to list by the end of the year. NEW YORK, NEW YORK, UNITED STATES, July 18, 2018 -- The first half of 2018’s IPO market saw several heavy hitters list. Most notably were Spotify, Dropbox and Xiaomi who were instrumental in seeing a 5% increase over 2017’s figures for the same period despite fewer companies coming to market.Spotify...

Published on .

Evolus, Inc. Announces Pricing of Public Offering of Common Stock

IRVINE, Calif., July 18, 2018 -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.  The offering consists of 3,000,000 shares offered by Evolus and 1,000,000 shares offered by a selling stockholder of Evolus, resulting in aggregate net proceeds of approximately $56.4 million to Evolus and approximately $18.8 million to the...

Published on .

Establishment Labs Announces Pricing of Initial Public Offering

NEW YORK, July 18, 2018 -- Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company focused on breast aesthetics and reconstruction technologies, today announced the pricing of its initial public offering of 3,715,277 common shares at a public offering price of $18.00 per share.  All of the common shares are being offered by Establishment Labs.  In addition, Establishment Labs has granted the underwriters a 30-day option to purchase up to 557,291 additional common...

Published on .

Scoping Study Delivers Outstanding Results

NEW YORK, July 18, 2018 -- Piedmont Lithium Limited (“Piedmont” or “Company”) (ASX:PLL) (NASDAQ:PLLL) is pleased to report the results of the Company’s Scoping Study for its vertically-integrated Piedmont Lithium Project (“Project”) located within the Carolina Tin-Spodumene Belt in North Carolina, USA (“TSB”).  The Project includes a lithium hydroxide chemical plant (“Chemical Plant”) supplied with spodumene concentrate from an open pit mine and concentrator (“Mine/Concentrator”).The...

Published on .

Carbonite Announces Pricing of Public Offering of Common Stock

BOSTON, July 18, 2018 -- Carbonite, Inc. (NASDAQ:CARB), a leader in data protection, today announced the pricing of an underwritten public offering of  4,765,157 shares of its common stock at the public offering price of $37.50 per share.  In addition, 698,080 shares beneficially owned by David Friend, a co-founder and director, have been offered by a selling stockholder at the public offering price.  Carbonite has granted the underwriters a 30-day option to purchase up to an additional...

Published on .

Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock

STAMFORD, Conn., July 18, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $19.00 per share. The offering is expected to close on or about July 23, 2018, subject to...

Published on .

VivoPower International PLC Reports Results for the Year Ended March 31, 2018

LONDON, July 18, 2018 -- VivoPower International, PLC (NASDAQ:VVPR) (“VivoPower”) an international solar power producer and storage company, today announced its financial results for the year ended March 31, 2018.“Fiscal 2018 was a challenging year for VivoPower,” said Carl Weatherley-White, VivoPower’s Chief Executive Officer. “Over the last six months, VivoPower has executed a strategic shift to prioritise solar development in the United States and Australia. Importantly, we have focused...

Published on .

AC Immune Announces Price of USD 11.75 for Offerings and Issuance of up to 10 Million Common Shares

Lausanne, Switzerland, July 19, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the price per common share of USD 11.75 for the offerings of up to 10 million new common shares of the Company. The offering price will be the same for all three offerings, the details of which were published yesterday, namely:The first subscription rights offering;The primary offering; andThe second subscription rights...

Published on .

OMA Announces Second Quarter 2018 Operating and Financial Results

MONTERREY, Mexico, July 18, 2018 -- Mexican airport operator Grupo Aeroportuario del Centro Norte, S.A.B. de C.V., known as OMA (NASDAQ:OMAB) (BMV:OMA), today reported its unaudited, consolidated financial and operating results for the second quarter of 2018. HighlightsAdjusted EBITDA grew 25.7%, with a margin of 70.5%Aeronautical and Non-Aeronautical revenues increased 16.0%Passenger traffic increased 9.6%33 commercial initiatives were implemented, including retail stores, restaurants, and...

Published on .

Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit

CAMBRIDGE, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc. announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S. Patent No. 9,340,830. Under the terms of the settlement, the lawsuit and counterclaims, as well as challenges to the patent in inter partes review, have been dismissed. Financial terms and other specifics of the settlement were not disclosed. About...

Published on .

BioArctic: Late breaking Phase 2b study results of BAN2401 in Alzheimer’s disease will be webcast live from AAIC 2018 by Eisai

Wed, Jul 18, 2018 22:00 CET Stockholm, Sweden, July 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B). As previously announced, the BAN2401 Phase 2b clinical study results will be presented in an oral session at the 2018 Alzheimer’s Association International Conference (AAIC) on July 25, 2018 at 3:30 p.m. CDT in Chicago, IL, as part of Session DT-01: “Recent Developments in Therapeutics” (2:00 p.m. to 4:00 p.m. CDT). The oral presentation will focus on the results of Phase 2b clinical...

Published on .

BONESUPPORT appoints Michael Diefenbeck as Head of Research & Development, Medical and Clinical Affairs

Wed, Jul 18, 2018 18:30 CET Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONESUPPORT’s Chief Medical Officer, has been appointed to assume a broader role as Head of R&D, Medical and Clinical Affairs. Emil Billbäck, CEO of BONESUPPORT, commented: “We are pleased to announce the expansion of Michael’s role to head of R&D, Medical and Clinical Affairs, where his...

Published on .

Athenex宣布Axis Therapeutics與香港理工大學簽訂諒解備忘錄,成立癌症免疫療法聯合研究中心

美國紐約州水牛城, July 18, 2018 -- Athenex, Inc.(NASDAQ:ATNX)是一間致力開發、研製和商業化癌症和相關疾病新療法的全球生物製藥公司,該公司今天宣布 Axis Therapeutics Limited與香港理工大學訂立諒解備忘錄(MOU),探討成立聯合研究中心,以便在香港推動免疫療法的應用。該聯合研究中心的最終目標是為全球癌症患者提供新穎的免疫療法。Axis Therapeutics是一間新成立的合資企業,由Athenex擁有55%股份,Xiangxue...

Published on .